Cambridge Healthtech Institute’s 15th Annual Discovery on Target brings the latest research in current and emerging “hot” targets, technologies and validation strategies for the development of novel small molecules and biologics.
Hear Domainex CSO, Trevor Perrior, present 'Building on Fragment-Based Drug Design' on Tuesday 26th September as part of the Lead Generation Strategies track. The talk will showcase FragmentBuilder - our fragment screening platform with MicroScale Thermophoresis at its core. It will be illustrated with case studies on the lysine methyltransferase, G9a; and on the work that led to the Domainex TBK1/IKKƐ inhibitor drug candidate, DMXD-011.
Trevor will be joined by Ray Boffey, Group Leader (Medicinal Chemistry) and Stefanie Reich, Prinicipal Protein Scientist. Why not call by our booth (#304) to see how we can support your drug discovery programme? We look forward to seeing you there.